Latest / The SPY Trader / S&P Savvy: Top Trades & Trends

Transcript

S&P Savvy: Top Trades & Trends · The SPY Trader

• 0:00
  Welcome to 'Spy Trader,
• 0:01
  ' the podcast that keeps you ahead of the S&P 500,
• 0:06
  I'm your host,
• 0:07
  Chuck Finansa,
• 0:08
  and it's 6:00 AM on September 24,
• 0:11
  2024,
• 0:12
  In today's episode,
• 0:13
  we'll discuss key news impacting the S&P 500,
• 0:17
  analyze these developments,
• 0:18
  and offer trading recommendations,
• 0:20
  First up,
• 0:21
  Starbucks has been downgraded to "underperform" by Jefferies analyst Andy Barish,
• 0:26
  with a new price target of $76,
• 0:29
  This follows a 30% surge since August 1st,
• 0:32
  reaching around $95,
• 0:34
  Barish cites operational challenges,
• 0:35
  underwhelming Q4 earnings guidance,
• 0:37
  and low EPS growth for fiscal 2025,
• 0:40
  Starbucks has also revised its 2024 global revenue growth to low single digits,
• 0:46
  down from 10%12%,
• 0:47
  Next,
• 0:48
  Eli Lilly’s Alzheimer's drug,
• 0:50
  donanemab,
• 0:50
  has been approved in Japan,
• 0:52
  a major market second only to the U,
• 0:56
  S,
• 0:56
  The stock rose modestly,
• 0:58
  now trading at about $919,
• 1:00
  01,
• 1:01
  In private equity,
• 1:02
  funds have raised 50,
• 1:04
  5% of total private capital in 2023,
• 1:07
  indicating outperformance,
• 1:08
  This trend highlights a strategic shift among private wealth investors toward experienced managers and diversified portfolios for resilience,
• 1:16
  Now,
• 1:16
  let’s dive into some analysis and insights:
• 1:27
  Brian Niccol's leadership will be crucial during this period,
• 1:31
  Eli Lilly’s approval of donanemab strengthens its market position and investor confidence,
• 1:36
  signaling strong future earnings potential,
• 1:38
  The increasing allure of private equity suggests highnetworth individuals are prioritizing longterm returns and resilience,
• 1:45
  which could impact the broader S&P 500,
• 1:48
  Now,
• 1:48
  onto our trading recommendations:
• 1:51
  Short Starbucks (SBUX): The downgrade and operational hurdles suggest potential stock correction,
• 1:56
  Monitor earnings reports and consumer sentiment for insights,
• 1:59
  2,
• 2:00
  Buy Eli Lilly (LLY): Approval of donanemab signals strong future earnings,
• 2:05
  making it a solid buy for stability and growth,
• 2:09
  3,
• 2:09
  Explore Private Equity Opportunities: Diversifying with private equity can provide longterm gains and mitigate risk,
• 2:16
  Consider highquality private equity funds,
• 2:18
  4,
• 2:19
  Monitor Tech Sector and Meta: Meta's AI investments have driven impressive growth,
• 2:24
  Stay updated on Meta’s developments to capitalize on potential gains in the tech sector,
• 2:30
  Lastly,
• 2:31
  a quick joke: Why was the financial planner so good at track?
• 2:36
  He really understood the hurdles,
• 2:38
  That’s all for this episode of 'Spy Trader,
• 2:42
  ’ Stay informed and make strategic decisions,
• 2:45
  Till next time,
• 2:46
  keep trading smart!